United States
Print page content Print
Increase text size Decrease text size
Text Size
CYTOPOINT is now approved for the treatment of allergic dermatitis! Learn more
Cytopoint logo

This site is intended for U.S.
animal healthcare professionals

CYTOPOINT®
side effects

CYTOPOINT® side effects

Adverse health events were comparable to placebo in client-owned dogs1*

Adverse Events Reported In >2% of Dogs in a Field Safety Study1†
Abnormal Health Event Preferred Term Placebo (N  = 83 dogs) CYTOPOINT (N = 162 dogs)
Otitis Externa 12.0% (10) 13.0% (21)
Dermatitis 13.3% (11) 9.9% (16)
Bacterial Skin Infection 12.0% (10) 9.3% (15)
Erythema 4.8% (4) 8.0% (13)
Vomiting 10.8% (9) 7.4% (12)
Anorexia 4.8% (4) 6.2% (10)
Lethargy 6.0% (5) 5.6% (9)
Pruritus 19.3% (16) 4.9% (8)
Diarrhea 4.8% (4) 3.7% (6)
Alopecia 7.2% (6) 2.5% (4)
  • Cases of vomiting, diarrhea and lethargy resolved without treatment1

  • Other than pruritus and alopecia, which were substantially more common in dogs receiving placebo.1
  • Occurrence calculated on a per-case basis—no matter how many observations of the same abnormal health event a dog had, it contributed one observation to the occurrence calculation.1

Indications: CYTOPOINT has been shown to be effective for the treatment of dogs against allergic dermatitis and atopic dermatitis.